Adt

Quick links to important sections

Adt

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adt

This foundational section defines the medicine Adt based on its core identity, classification, and general purpose.

Property Description
Active ingredient Amitriptyline
Form Oral tablets, Oral solution
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Modulating mood and managing chronic nerve pain
Origin Synthetic compound (First-generation)

What Type of Medicine is Adt?

Adt is a prescription medication whose active ingredient is Amitriptyline, a synthetic compound classified as a Tricyclic Antidepressant (TCA). This classification identifies it as a first-generation psychotropic drug designed to stabilize the central nervous system. As a member of the TCA class, Amitriptyline's mechanism involves modulating the availability of the monoamines serotonin and norepinephrine, essential chemical messengers involved in mood regulation and pain perception. The clinical recognition of its broad action profile sets it apart from newer, more selective agents, establishing its continued relevance in the medical community.

Composition and General Purpose

The core component of the medicinal entity Adt is the single active ingredient, Amitriptyline, typically provided as the hydrochloride salt. This formulation is primarily manufactured as oral tablets or, less commonly, as a liquid oral solution, both designed for oral administration. The general purpose of the TCA class, including Amitriptyline, is to help modulate mood stability and alleviate specific forms of chronic, persistent pain. For instance, it is commonly used to address discomfort arising from nerve damage that is often unresponsive to traditional painkillers. The medication is utilized in the management of such pain. This demonstrates its foundational role as a dual-utility agent with applications beyond its initial antidepressant classification, a feature that differentiates it from most selective serotonin modulators.

Regulatory References

  1. NICE: Neuropathic pain in non-specialist settings: pharmacological management

What side effects are possible with Adt?

Possible Side Effects and Safety Information

Official regulatory documents from government health authorities categorize the known risks and possible adverse reactions associated with Adt.

Adverse Reactions Scope

Adverse reactions are classified by their frequency (e.g., Very Common, Common, Uncommon, Rare) and are grouped by the body system affected, known as System-Organ Classes (SOCs). These SOCs include effects on the Blood and Lymphatic System, Nervous System, Gastrointestinal System, Hepato-biliary System, Skin and Subcutaneous Tissue, and General disorders.

Frequency Classification Example System-Organ Classes
Very Common General disorders, Nervous System disorders
Common Cardiac disorders, Musculoskeletal disorders, Skin disorders
Uncommon to Rare Immune System disorders, Hepato-biliary disorders

Serious Adverse Reactions

The regulatory safety profile highlights certain reactions requiring immediate medical attention. These officially documented serious adverse reactions include severe hypersensitivity reactions, such as anaphylaxis, and severe skin reactions like Stevens-Johnson syndrome or Toxic Epidermal Necrolysis.

Safety-Related Restrictions

Official labeling includes specific contraindications (situations where the medicine should not be used) primarily due to known hypersensitivity to the active substance or excipients, or in patients with severe hepatic (liver) impairment. Other restrictions involve specific safety considerations for use in populations such as pediatric patients, pregnant or breastfeeding women, and patients with pre-existing renal or hepatic impairment. Close monitoring of liver function tests and blood counts is defined in official documents as a necessary precaution during treatment.

Overdose and Emergency Response

The official regulatory profile for Adt (Amitriptyline) overdose defines it as a serious medical emergency primarily involving the central nervous system (CNS) and the cardiovascular system. Due to the high risk of life-threatening outcomes, immediate medical attention must be sought for any suspected overdose, and users are instructed to contact emergency services without delay.

Domain Documented Manifestations
CNS/Neurological Drowsiness, confusion, agitation, stupor, coma, seizures, tremor, and muscle rigidity.
Cardiovascular Severe hypotension, ventricular dysrhythmias, QRS complex widening on ECG, and potential cardiac arrest.
Autonomic Dilated pupils (mydriasis), urinary retention, and profound dry mouth.

Management is defined as symptomatic and supportive treatment, as no specific antidote is known to reverse the toxicity. Officially described supportive measures include continuous ECG monitoring and observation of vital signs. Other measures may include alkalinization with sodium bicarbonate for cardiac toxicity and the use of activated charcoal for recent ingestions.

Hospital admission is mandated for observation and monitoring due to the risk of delayed severe effects. The elderly population may exhibit increased susceptibility to these overdose effects.

Therapeutic Uses of Adt

What Adt Treats: Main Uses and Benefits

Adt (Amitriptyline) is commonly used for managing symptomatic discomfort across two primary therapeutic axes, provides supportive relief for conditions that affect both the nervous system and mood. Its applications include these therapeutic areas.

This medication is applied across domains where additional symptomatic support is needed, primarily for major depressive disorder, chronic nerve pain (neuropathic pain), and the prophylactic management of recurrent headaches.


Management of Symptoms and Patient Benefit

In clinical settings, Adt is commonly used to help with symptoms related to chronic nerve pain, particularly symptoms related to heightened physiological activity. It supports relief for symptoms related to physical discomfort. It is also applied to manage low mood and emotional distress in patients with mood disorders. A key benefit may be the support it provides in easing the overall symptom burden and assisting with maintaining functional stability.

“It is relevant when supportive symptom management is appropriate and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Chronic Discomfort
Adt is relevant for managing symptoms that interfere with daily comfort.

Prevention of Recurrent Pain

Adt is also considered relevant in the field of preventive medicine, and is commonly used to help with managing symptoms that interfere with daily functioning, specifically for recurrent or episodic manifestations like migraine headaches and chronic tension headaches. This treatment supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Amitriptyline

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Adt — Official Regulatory Information

Eligibility scope

Category Status (Regulatory Basis)
Allowed Adults (18 years and older); Children ge 6 years for the specific indication of nocturnal enuresis.
Contraindicated Patients with known hypersensitivity; Concurrent use with Monoamine Oxidase Inhibitors (MAOIs); Acute recovery phase following a myocardial infarction; Severe arrhythmias or heart block; Severe hepatic disease.
Not Recommended Children and adolescents under 18 years for most uses where safety is not fully established; Patients who are breastfeeding.

Condition-specific eligibility rules

Use requires caution and close monitoring in populations with several pre-existing conditions, including a history of seizures, angle-closure glaucoma, or cardiovascular disorders. Patients with impaired liver function or those aged 65 years and older typically require highly cautious initiation. Use during pregnancy is classified as Category C, meaning it is permitted only if the potential benefit to the mother justifies the potential risk to the fetus.

Connection to the overall eligibility profile

Official regulatory documents establish eligibility for Adt by formally defining who is strictly prohibited from use (contraindications) and who requires restricted or conditional use. Prohibitions center on acute cardiac status, known hypersensitivity, and concurrent MAOI therapy. Age restrictions generally exclude children under six years for all uses and advise against use in adolescents for most indications where safety has not been fully established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adt (Amitriptyline) is susceptible to officially documented pharmacokinetic and pharmacodynamic interactions. All interaction information is based strictly on government regulatory sources.


Formal Contraindications and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of Serotonin Syndrome. A mandatory 14-day washout period is required when starting or stopping either medication. Combination with Cisapride is also prohibited due to the potential for QT interval prolongation, a documented pharmacodynamic risk. Pimozide is similarly contraindicated.


Alterations in Exposure

Adt is metabolized by Cytochrome P450 (CYP) enzymes. Substances that inhibit CYP2D6 (e.g., Fluoxetine, Paroxetine, Quinidine) or CYP1A2 (e.g., Fluvoxamine) are documented to increase Adt’s plasma concentration and systemic exposure. Conversely, strong enzyme inducers (e.g., Carbamazepine, Phenytoin) are noted to reduce exposure.


Additive Pharmacodynamic Effects

Official labeling documents significant additive effects when Adt is combined with other agents:

  • CNS Depressants: Substances like alcohol and opioids are noted to potentiate the sedative and CNS depressant effects of Adt.
  • Anticholinergic Agents: Co-use with other anticholinergic drugs increases the risk of additive peripheral effects.

Interaction severity is a particular consideration for elderly patients, due to heightened susceptibility to CNS depression and anticholinergic effects.

Mechanism of Action

Adt functions as a competitive antagonist, binding selectively to beta1-adrenergic receptors. These receptors are primarily situated on cardiac pacemaker cells and myocardial tissue.

By occupying the beta1 receptor binding site, the drug molecule prevents the attachment and subsequent action of endogenous catecholamines, specifically norepinephrine and epinephrine.

This competitive interaction directly leads to the modulation of the adenylate cyclase signaling pathway. The blockade reduces the enzyme's activity, which effectively lowers the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).

The resulting downstream mechanistic cascade involves a reduction in calcium ion influx into the myocardial cells, which affects cellular excitability and contractility. The resulting system-level physiological consequences are a decrease in the rate of sinoatrial node firing (negative chronotropy) and a reduced myocardial force of contraction (negative inotropy).

Dosage and Administration Information

How to Use Adt: Administration and Dosing

The administration of Adt (Amitriptyline) is defined by specific guidelines which govern the approved routes, dose ranges, frequency, and duration of use. The following parameters describe the established clinical guidelines for the medication.


Administration Scope

Usage Guideline Clinical Instruction
Route of Administration Primarily oral (swallowed via mouth).
Preparation Tablets should be swallowed whole with water, and intake is permitted with or without food.
Standard Dosing Therapy typically starts low and is gradually increased (titrated). For adult outpatients, the starting dose is often 75 mg daily (divided) or 50 mg to 100 mg once daily at bedtime. Maintenance doses are generally 50 mg to 100 mg daily.
Frequency Dosing may be once daily (often at bedtime) or in divided doses.

Specific Use Patterns

The use of Adt requires adherence to specific protocols for initiation, duration, and cessation.

  • Population Adjustments: Lower starting doses are utilized for older adults (e.g., 50 mg daily). A 50% reduction in the starting dose is often advised for patients with hepatic impairment.
  • Duration and Withdrawal: Maintenance treatment is generally recommended for at least three months. Discontinuation must be achieved by gradually reducing (tapering) the dose to avoid potential withdrawal effects.
  • Missed Dose Rule: If a dose is missed and it is almost time for the next scheduled dose, the standard procedure is to skip the missed dose and resume the regular schedule.

These instructions define the standardized, procedural steps for taking the medicine, ensuring that the route, dose, and frequency align with established specifications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adt


Evidence for Use in Major Depressive Disorder

The research base for Adt's evaluation in conditions characterized by fluctuating or episodic manifestations largely consists of short-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies were used in research exploring how symptoms change over time in adults diagnosed with major depressive disorder, including those with higher severity. Findings from meta-analyses described patterns observed in the studies related to changes in symptom scores. Evidence related to this evaluation is broadly considered to have a Moderate level of certainty.

Evidence for Use in Chronic Nerve Pain

This evidence foundation is based on a collection of short-to-intermediate term, placebo-controlled RCTs and systematic reviews. Research explored Adt's evaluation in conditions where symptoms may vary in intensity, focusing on outcomes related to physical discomfort from nerve damage. Data show patterns related to changes in pain intensity measured over short treatment periods. The formal research for this evaluation is often considered to have a Low level of certainty due to the prevalence of small, older trials and variable evidence quality.

Long-Term Studies and Follow-Up

The majority of the evidence related to Adt's evaluation comes from studies with limited follow-up durations, focusing primarily on the acute phases of symptom management. This means there is limited information for long-term outcomes regarding the durability of the symptom patterns observed during treatment. Research exploring short-term symptom changes is more available than evidence describing long-term durability.

What Remains Uncertain About Adt's Research Base

One main limitation is the variable evidence quality across studies. Furthermore, a significant portion of the evidence is historical, with study designs that do not always meet the rigorous standards expected of current clinical trials. Comparative evidence is lacking for many head-to-head comparisons against newer, more selective drugs. The research provides context but not individual predictions, and the evidence base has modest sample sizes in many key trials.

Key Studies & References

  1. MedlinePlus: Amitriptyline
  2. NICE Clinical Guideline CG173: Neuropathic pain in non-specialist settings: pharmacological management (Recommendations Section)

Frequently Asked Questions (FAQ)

Common questions about Adt (FAQ)

Q: How quickly should I expect to feel a difference after starting Adt?

A: Studies and official information indicate that a noticeable effect may take time. For conditions like depression, the maximum benefit may not be apparent until approximately 30 days after beginning therapy. For other uses, it may take 4 to 6 weeks before signs of improvement are seen.

Q: Is it normal to feel tired when first starting Adt?

A: Yes, regulatory information lists drowsiness, weakness, and fatigue as common side effects associated with Adt, particularly in the initial phases of treatment. Regulatory dosing guidance often suggests taking the medicine at bedtime, which can help manage daytime drowsiness.

Q: Can Adt affect my sleep patterns?

A: Official product information notes that Adt can cause difficulty falling asleep or staying asleep (insomnia) and nightmares as potential side effects. The medication is frequently administered at bedtime, a timing decision often related to its sedating properties.

Q: Will Adt affect my ability to drive or operate machinery?

A: Due to the risk of drowsiness, official warnings state that activities requiring alertness, such as driving or operating heavy machinery, should be avoided until the drug's effect is known. This is a standard precaution related to the medication’s potential effects on the nervous system.

Q: Is it necessary to have regular blood tests while taking Adt?

A: Official monitoring guidelines state that close monitoring of liver function tests and a complete blood count (CBC) may be necessary, especially at the start of treatment. This is part of the standardized protocol for managing potential safety risks.

Q: What happens if I accidentally take a double dose of Adt?

A: Adt overdose can be a serious medical concern. If a dose exceeding the prescribed amount is taken, it is necessary to seek emergency medical attention immediately, as outlined in regulatory information. You should also contact a Poison Help line or emergency services.

Q: Does the time of day I take Adt matter?

A: Official dosing instructions state that the total daily dose may be given as a single dose, preferably at bedtime. This timing is often utilized due to the medicine's known sedative effects.

Q: Can Adt be taken during pregnancy or while breastfeeding?

A: For pregnancy, use is classified as Category C, meaning it is only permitted if a professional deems the potential benefit to outweigh the potential risk to the fetus. For breastfeeding, official information indicates Adt is released into breast milk, and use is generally not recommended or requires professional evaluation of risks and benefits.

Q: Will Adt interact with birth control pills?

A: Authoritative medical criteria do not generally list Adt among the medications known to significantly reduce the effectiveness of hormonal contraceptives, such as birth control pills. However, it is standard medical practice to discuss all medications, including hormonal contraceptives, with a healthcare professional.

Q: How long can a person safely stay on Adt?

A: For certain uses, such as major depressive disorder, maintenance treatment is officially recommended for at least three months to help prevent relapse. Continued use beyond this period is typically managed by a healthcare professional through regular medical review and monitoring.

Q: Can Adt cause any problems with dental work or surgery?

A: Regulatory warnings state that it is necessary to inform the dentist or surgeon about taking Adt. This is because combining Adt with certain anesthetics or other medicines used during a procedure may increase the risk of side effects.

Q: How does Adt affect a person's mood or energy levels?

A: As a Tricyclic Antidepressant, Adt's primary action involves modulating mood stability. However, the medication is also known for its sedative properties, which can cause common side effects such as drowsiness and weakness, potentially leading to reduced energy levels.

How should Adt be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory agencies define strict rules for the storage and disposal of Adt (Amitriptyline) to ensure product stability and safety. The medicine must be kept at room temperature, typically defined as below 30 C, and protected from light and moisture to prevent degradation. This requires storing the tablets in their original container with the cap tightly closed and ensuring they are not frozen.

For safety, it is mandatory to keep Adt out of the sight and reach of children.

When disposing of unused or expired medicine, it must be done in accordance with local regulations. The drug must not be flushed down the toilet or allowed to enter the wastewater system; instead, utilize a designated drug take-back program or follow official trash disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adt found in:

A-Z Index: